Keros Therapeutics, Inc.

Quick facts

Phase 2 pipeline

• Dose A KER-012
• Dose B KER-012 · Bone disorders
  Dose B KER-012 is a bone morphogenetic protein (BMP) agonist.
• Dose C KER-012

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Keros Therapeutics, Inc. portfolio CI brief
• Keros Therapeutics, Inc. pipeline updates RSS

Related

• Sector hub: All tracked pharma companies